Data on file, Abbott Diabetes CareĢAlva, Shridhara, Timothy Bailey, Ronald Brazg, Erwin S.
We've done that again with FreeStyle Libre 3, the smallest sensor that delivers life-changing benefits and best-in-class accuracy," said Jared Watkin, senior vice president, Diabetes Care, Abbott.Ībbott is launching the FreeStyle Libre 3 system in Europe in the coming months.ġAmong patient-applied sensors. "Abbott won't stop innovating when there's room to raise the bar. This number is projected to balloon 51% to 700 million people by 2045, IDF data show. This continuous innovation shows Abbott's strength in the market, which is vast and growing with 463 million adults living with diabetes, according to the International Diabetes Federation (IDF). Food and Drug Administration for adults and kids ages 4 and up with diabetes Libre Sense Glucose Sport Biosensor was CE marked in September for athletes ages 16 and up who don't have diabetes and now, FreeStyle Libre 3 has received CE mark for ages 4 and up with diabetes. In just four months, Abbott has achieved three key milestones for its sensor-based glucose monitoring tech: FreeStyle Libre 2 was cleared in June by the U.S. Affordable 6 - To allow as many people as possible living with diabetes to access and benefit from the tech, Abbott's FreeStyle Libre 3 system will be priced the same as previous generations of the device, which is a third of the cost of other CGMs available.More environmentally sustainable - Reducing the system's total volume by more than 70%, 5 Abbott designed FreeStyle Libre 3 to be more sustainable for the environment, including a 41% reduction in plastic use and 43% decrease in carton paper.This latest tech and FreeStyle Libre 2 are the only CGM sensors sustaining a high level of accuracy over 14 days. Unsurpassed 14-day accuracy 2 - The FreeStyle Libre 3 system has a mean absolute relative difference (MARD), a measurement of performance for CGMs, of 9.2% for adults.4 This is a life-changing innovation that lets people live better and gain deeper understanding of their glucose levels.Ībbott's FreeStyle Libre 3 is unparalleled in the market, here's why: The FreeStyle Libre 3 system is designed to fit seamlessly into people's lives, enabling users to discreetly check their glucose as often as they like without having to fingerstick. "Continued momentum for the global Libre franchise" is expected, Cowen analysts wrote in a June 15 note. This next-gen system provides the same benefits of FreeStyle Libre 2, including unsurpassed 14-day 2 accuracy and optional glucose alarms, but also evolves the portfolio with new features, such as continuous real-time glucose readings automatically delivered to a person's smartphone every minute and a sensor that's easy to apply with a one-piece applicator. pennies) - has received CE mark for people with diabetes in Europe. The much-anticipated FreeStyle Libre 3 system - featuring the world's smallest, thinnest 1 glucose sensor (about the size of two stacked U.S. Nearly 85% said managing chronic conditions across their workforce is a priority.Abbott has kept a steady drumbeat of innovation across its FreeStyle portfolio in 2020 and the company isn’t about to break its streak now.
Livongo is among a wave of digital health startups capitalizing on the push by providers and employers to manage the cost of chronic conditions as the country moves to more risk-based payment models.Ī recent survey by Willis Towers Watson found that 76% of employers planned to invest in diabetes support tools and solutions in 2019, in an effort to improve employee health and lower costs. Livongo said it is the first digital health company to incorporate continuous glucose data from the FreeStyle Libre system into its platform. Sales in the diabetes business have grown by more than 30% for three quarters in a row.Ībbott’s FreeStyle Libre devices compete with Dexcom’s G6 continuous glucose monitor, Senseonics’ Eversense and Medtronic’s Guardian Connect. The devices helped drive a 40% surge in sales in Abbott’s diabetes division in the second quarter. In July, FDA approved FreeStyle Libre with a 14-day sensor.īeing able to avoid routine fingersticks to test blood sugar levels has proved popular with patients.
FREESTYLE LIBRE FLASH GLUCOSE MONITORING SYSTEM FOR SALE PRO
The Pro model received FDA approval in September 2016, followed a year later by the FreeStyle Libre Flash glucose monitoring system with a 10-day sensor. Abbott has a big hit on its hands with its FreeStyle Libre glucose monitors that don't require patients to enter fingerstick data.
0 kommentar(er)
